| Dr Byron Drake Erstine, DO | |
|
2907 Hillrise Dr, Las Cruces, NM 88011-4701 | |
| (575) 449-8949 | |
| Not Available |
| Full Name | Dr Byron Drake Erstine |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 20 Years |
| Location | 2907 Hillrise Dr, Las Cruces, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487847174 | NPI | - | NPPES |
| 200245010A | Medicaid | OK | |
| 177624003 | Medicaid | AR | |
| 21423059 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | A-1900-15 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mountain View Regional Medical Center | Las cruces, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| National Sinus Institute Pllc | 9234284407 | 31 |
News Archive
While deployed in combat zones, U.S. armed forces prepare for the rigors of combat and stay in peak condition by lifting weights during intense and demanding workouts.
President Obama got serious this week about the ticking time bomb in his new health-care legislation - the lack of any clear plan to reduce costs and improve quality. What he did was install someone who can use our behemoth Medicare and Medicaid programs as laboratories for change - so that reform doesn't bankrupt the country (David Ignatius, 7/9).
The Commission on Cancer of the American College of Surgeons has granted its Outstanding Achievement Award to a select group of 90 currently accredited and newly accredited cancer programs across the United States as a result of surveys performed during 2010.
The brain never sits idle. Whether we are awake or asleep, watch TV or close our eyes, waves of spontaneous nerve signals wash through our brains. Researchers at the Salk Institute for Biological Studies studying visual attention have discovered a novel mechanism that explains how incoming sensory signals make themselves heard amidst the constant background rumblings so they can be reliably processed and passed on.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
› Verified 2 days ago
| Entity Name | National Sinus Institute Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194968081 PECOS PAC ID: 9234284407 Enrollment ID: O20090911000511 |
News Archive
While deployed in combat zones, U.S. armed forces prepare for the rigors of combat and stay in peak condition by lifting weights during intense and demanding workouts.
President Obama got serious this week about the ticking time bomb in his new health-care legislation - the lack of any clear plan to reduce costs and improve quality. What he did was install someone who can use our behemoth Medicare and Medicaid programs as laboratories for change - so that reform doesn't bankrupt the country (David Ignatius, 7/9).
The Commission on Cancer of the American College of Surgeons has granted its Outstanding Achievement Award to a select group of 90 currently accredited and newly accredited cancer programs across the United States as a result of surveys performed during 2010.
The brain never sits idle. Whether we are awake or asleep, watch TV or close our eyes, waves of spontaneous nerve signals wash through our brains. Researchers at the Salk Institute for Biological Studies studying visual attention have discovered a novel mechanism that explains how incoming sensory signals make themselves heard amidst the constant background rumblings so they can be reliably processed and passed on.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Byron Drake Erstine, DO 1620 N Main St, Spanish Fork, UT 84660-1008 Ph: (801) 822-2234 | Dr Byron Drake Erstine, DO 2907 Hillrise Dr, Las Cruces, NM 88011-4701 Ph: (575) 449-8949 |
News Archive
While deployed in combat zones, U.S. armed forces prepare for the rigors of combat and stay in peak condition by lifting weights during intense and demanding workouts.
President Obama got serious this week about the ticking time bomb in his new health-care legislation - the lack of any clear plan to reduce costs and improve quality. What he did was install someone who can use our behemoth Medicare and Medicaid programs as laboratories for change - so that reform doesn't bankrupt the country (David Ignatius, 7/9).
The Commission on Cancer of the American College of Surgeons has granted its Outstanding Achievement Award to a select group of 90 currently accredited and newly accredited cancer programs across the United States as a result of surveys performed during 2010.
The brain never sits idle. Whether we are awake or asleep, watch TV or close our eyes, waves of spontaneous nerve signals wash through our brains. Researchers at the Salk Institute for Biological Studies studying visual attention have discovered a novel mechanism that explains how incoming sensory signals make themselves heard amidst the constant background rumblings so they can be reliably processed and passed on.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
› Verified 2 days ago
Colin Byrd, D.O. Otolaryngology Medicare: Medicare Enrolled Practice Location: 2450 S Telshor Blvd, Las Cruces, NM 88011 Phone: 575-522-8641 | |
Dr. Vittal T Pai, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2415 S Telshor Blvd, Las Cruces, NM 88011 Phone: 575-522-7977 Fax: 575-522-0930 | |
Terry H Mcmillan, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1130 Commerce Dr, Las Cruces, NM 88011 Phone: 505-521-3025 |